The lack of effect of a prophylactic dose of enoxaparin on thrombin generation in patients subjected to nephrectomy because of kidney cancer

Thrombosis Research

Volumn 104, Issue 6, 2001, Pages 427-432

  Szczepański, Maciej ^a   Szostek, Przemyslaw ^a   Pypno, Wojciech ^a   Borówka, Andrzej ^a  

^a MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

Author keywords

Enoxaparin; Surgery; Thrombin generation

Indexed keywords

ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLASMIN; PLASMIN INHIBITOR; THROMBIN; THROMBIN ANTITHROMBIN COMPLEX;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME BLOOD LEVEL; FEMALE; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; MALE; NEPHRECTOMY; PERIOPERATIVE PERIOD; PERITONEUM; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; THROMBOEMBOLISM;

ADULT; AGED; ANTITHROMBIN III; ENOXAPARIN; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOLYTIC AGENTS; HUMANS; INTRAOPERATIVE PERIOD; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEPHRECTOMY; PEPTIDE HYDROLASES; POSTOPERATIVE PERIOD; THROMBIN; THROMBOSIS;

EID: 0035894598     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(01)00394-2     Document Type: Article

References (25)

1. Low molecular weight heparins. Prophylaxis of venous thromboembolism in surgical patients
2. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: A double-blind randomized multicentre trial with venographic assessment
3. Prophylaxis of venographically diagnosed deep vein thrombosis in gastrointestinal surgery
4. Low molecular weight heparins: Current use and indications
5. Low-molecular-weight heparins
6. Laboratory markers of coagulation activation
7. Enoxaparin, low molecular weight heparin: Its use in the prevention of deep venous thrombosis following total hip replacement
8. Low-molecular-weight heparin (enoxaparin) vs. dextran 70. The prevention of postoperative deep vein thrombosis after total hip replacement
9. Involvement of the extrinsic pathway in the activities of low molecular weight heparins
10. Components of coagulation and fibrinolysis during thrombosis prophylaxis with low molecular weight heparin (enoxaparin) versus dextran 70 in hip arthroplasty
11. Thrombin-antithrombin III complex and fibrin degradation products in plasma: Surgery and postoperative deep venous thrombosis
12. The low molecular weight heparin enoxaparin inhibits the consumption of factor VII and prothrombin activation in vivo associated with elective knee replacement surgery
13. Thrombin-antithrombin III complexes for the detection of postoperative hypercoagulable state in surgical patients receiving heparin prophylaxis
14. The influence of LMW heparin on the coagulation and fibrinolysis response to surgery
15. The effect of subcutaneous injection of unfractionated and low molecular weight heparin on thrombin generation in platelet rich plasma - A study in human volunteers
16. Pathogenesis of venous thrombosis: A new insight
17. Low-dose low-molecular-weight heparin is anti-inflammatory during venous thrombosis
18. Heparin: A unique misunderstood drug
19. Perioperative fibrinolytic activity in cholecystectomized patients. The postoperative fibrinolytic shutdown is only a temporary event
20. Fibrinolytic shut-down after surgery
21. The influence of laparoscopic cholecystectomy on perioperative blood clotting and fibrinolysis
22. Plasma fibrinolytic activity in patients undergoing major abdominal surgery
23. The postoperative fibrinolytic shutdown: A rapidly reverting acute phase pattern for the fast-acting inhibitor of tissue-type plasminogen activator after trauma
24. Postoperative hypercoagulable state followed by hyperfibrinolysis related to wound healing after hepatic resection
25. Association between plasma levels of tissue plasminogen activator and postoperative deep vein thrombosis - Influence of prophylaxis with a low molecular weight heparin